Supplementary Table 1 Deregulated miRNAs in the tissues of breast cancer
miRNA / Alteration / Tissue(N) / Pathological features relationship / Ref.
miR-10b, 125a,125b
miR-145, 21, 155 / Down
Up / 76 BC / ER,PR status: miR-30；
Tumor stage: miR-203；
LN status: miR-9-3,let-7a；
Grade: miR-145,102，let-7c,d / [1]
miR-342
miR-520g / 95 BC / ER status: miR-342
PR status: miR-520cfg
HER2: miR-520d,181c,302c / [2]
miR-155 / Up / 144 BC / [3]
miR-206 / Down / 94 BC / ERα positive / [4]
miR-183 / 70 BC / ERα / [5]
miR-92 / 28 BC / ERb1 / [6]
miR-221，222 / Up / 41 BC / ERα negative / [7]
let-7 / Up / 15 BC / ERα positive / [8]
miR-106b, 342, 18a, 17-92, 135b, 505, 181a, 29c / 103 LNNBC / Lymph node status / [9]
miR-21 / 95 BC / LN metastasis
Shortened survival / [10]
miR-21 / 344 BC / [11]
miR-145，205
miR-21 / Down
Up / 100 BC / [12]
miR-210 / Up / 219 BC / Disease-free survival
Overall survival / [13]
miR-10b / Up / 219 BC / [14]
miR-450a，148a, 30b, 150, 155
miR-99a, 99b, 205, 130b, 24, 125b / Up
Down / 13 primary BC
Metastatic LN / [15]
miR-373
miR-520c / Up / 72 BC
11 primary BC
metastatic LN / [16]
miR-31 / 54 BC / [17]
miR-7，128a，210,516b / 299 LNNBC / prognosis / [18]
miR-30c / 246 ER positive BC / Tamoxifen treatment / [19]
miR-93，106b，25 / Up / 93 BC / [3]
miR-27b / Down / 24 BC / [20]
miR-17 / Down / 16 BC / [21]
miR-9 / Down / 71 BC / [22]
miR-203 / Up / 76 BC / [1]
let-7d, miR-210, miR-221 / 80 IDC;
8 ductal BC / Prognosis / [23]
Reference
1. Iorio MV, Ferracin M, Liu CG et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65 (16):7065-7070
2. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93 (9):1046-1052
3. Navin N, Kendall J, Troge J et al (2011) Tumour evolution inferred by single-cell sequencing. Nature 472 (7341):90-94
4. Brase JC, Johannes M, Schlomm T et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128 (3):608-616
5. Mestdagh P, Van Vlierberghe P, De Weer A et al (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10 (6):R64
6. Igglezou M, Vareli K, Georgiou GK et al (2014) Kinetics of Circulating Levels of miR-195, miR-155 and miR-21 in Patients with Breast Cancer Undergoing Mastectomy. Anticancer Res 34 (12):7443-7447
7. Pimentel F, Bonilla P, Ravishankar YG et al (2014) Technology in MicroRNA Profiling: Circulating MicroRNAs as Noninvasive Cancer Biomarkers in Breast Cancer. J Lab Autom
8. Zhao Y, Deng C, Wang J et al (2011) Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127 (1):69-80
9. Keller A, Leidinger P, Vogel B et al (2014) miRNAs can be generally associated with human pathologies as exemplified for miR-144*. BMC Med 12 (1):224
10. Xiang M, Zeng Y, Yang R et al (2014) U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun 454 (1):210-214
11. Epstein DM (2014) Special delivery: microRNA-200-containing extracellular vesicles provide metastatic message to distal tumor cells. J Clin Invest 124 (12):5107-5108
12. Sempere LF, Christensen M, Silahtaroglu A et al (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67 (24):11612-11620
13. Camps C, Buffa FM, Colella S et al (2008) hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14 (5):1340-1348
14. Hatse S, Brouwers B, Dalmasso B et al (2014) Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One 9 (10):e110644
15. Baffa R, Fassan M, Volinia S et al (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219 (2):214-221
16. Cui Z, Lin D, Song W et al (2014) Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study. Tumour Biol
17. Liu L, Wang S, Cao X et al (2014) Analysis of circulating microRNA biomarkers for breast cancer detection: a meta-analysis. Tumour Biol 35 (12):12245-12253
18. Foekens JA, Sieuwerts AM, Smid M et al (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105 (35):13021-13026
19. Park IH, Kang JH, Lee KS et al (2014) Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer. Tumour Biol 35 (12):12173-12180
20. Jarry J, Schadendorf D, Greenwood C et al (2014) The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 8 (4):819-829
21. Wang R, Wen H, Xu Y et al (2014) Circulating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: a meta-analysis based on 42 articles. PLoS One 9 (11):e113401
22. Zhang ZY, Dai ZL, Yin XW et al (2014) Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer. Bmc Cancer 14:773
23. Volinia S, Galasso M, Sana ME et al (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 109 (8):3024-3029